⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2494 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL17303190 | 0.97 | — | — | |
| SCHEMBL29138664 | 0.85 | — | — | |
| Cadaverine Tartrate SCHEMBL7865850 | 0.78 | TSHR (0.39) | — | |
| Cadaverine Tartrate SCHEMBL9163185 | 0.77 | TSHR (0.37) | — | |
| Hydrochloric Acid SCHEMBL5490018 | 0.77 | — | — | |
| SCHEMBL29771444 | 0.75 | — | — | |
| SCHEMBL84535 | 0.71 | — | — | |
| SCHEMBL84537 | 0.71 | — | — | |
| SCHEMBL84536 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4100010-B1 | NITROXIDE COMPOUNDS FOR USE IN THE TREATMENT OF OPIOID-INDUCED RESPIRATORY DEPRESSION (OIRD) | UNIV CASE WESTERN RESERVE (US) | 2026-01-07 | — | — | EP | claimed |
| EP-3180349-B1 | LYMPH DIRECTING PRODRUGS AND THERAPEUTIC USES THEREOF | UNIV MONASH (AU) | 2025-03-12 | — | — | EP | claimed |
| EP-3441087-B1 | METHODS OF TREATING CHRONIC PAIN | TEVA PHARMACEUTICALS INT GMBH (CH) | 2025-02-19 | — | — | EP | claimed |
| EP-3706762-B1 | N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO | UNIV EMORY (US) | 2024-10-16 | — | — | EP | claimed |
| EP-3863708-B1 | MIXED IONIC CONDUCTORS AND CORRESPONDING DEVICES, SYSTEMS AND METHODS OF MAKING | BATTELLE MEMORIAL INSTITUTE (US) | 2024-09-11 | — | — | EP | claimed |
| EP-3768679-B1 | BIASED POTENT OPIOID-LIKE AGONISTS AS IMPROVED MEDICATIONS TO TREAT CHRONIC AND ACUTE PAIN AND METHODS OF USING THE SAME | US HEALTH (US) | 2024-06-26 | — | — | EP | claimed |
| EP-1962797-B2 | POWDER COMPOSITIONS FOR INHALATION | JAGOTEC AG (CH) | 2024-05-29 | — | — | EP | claimed |
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-0300806-B1 | Opioid analgesic liposomal delivery-release system | VESTAR INC (US) | 1994-09-07 | — | — | EP | claimed |
| EP-0367746-B1 | Sustained release drug-resin complexes | RICHARDSON VICKS INC (US) | 1994-02-02 | — | — | EP | claimed |
| EP-0441833-B1 | DOSAGE FORM HAVING REDUCED ABUSE POTENTIAL | ALZA CORPORATION (US) | 1993-09-08 | — | — | EP | claimed |
| WO-1993002707-A1 | NEW ANTI-DIARRHEIC AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1993-02-18 | — | — | WO | claimed |
| EP-0375689-B1 | A PHARMACEUTICAL COMPOSITION ADAPTED FOR TRANSDERMAL DELIVERY OF AN OPOID DRUG. | WARNER-LAMBERT COMPANY (US) | 1992-08-12 | — | — | EP | claimed |
| EP-0287469-B1 | MIXTURE CONTAINING AS THE ACTIVE PRINCIPLES A CENTRAL ANALGESIC AND FORSKOLIN | ROUSSEL-UCLAF (FR) | 1992-07-08 | — | — | EP | claimed |
| EP-0108017-B1 | MIXTURE COMPRISING A CENTRAL ANALGESIC AND VITAMIN B12, OR ONE OF ITS ANALOGS, AS ACTIVE PRINCIPLES | ROUSSEL-UCLAF (FR) | 1986-12-10 | — | — | EP | claimed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
| EP-0036145-B1 | AN ORALLY ADMINISTERED DRUG FORM COMPRISING A POLAR BIOACTIVE AGENT AND AN ADJUVANT | INTERx RESEARCH CORPORATION (US) | 1985-05-29 | — | — | EP | claimed |